Trader consensus prices "No" at 82.5% for a new COVID variant of concern before 2027, reflecting the World Health Organization's stringent criteria unmet by recent SARS-CoV-2 subvariants despite vigilant global surveillance. The highly mutated BA.3.2 ("Cicada") lineage, a variant under monitoring with over 70 spike protein changes, surged in U.S. wastewater across 31 states and Europe through April 2026 but shows no elevated severity, transmissibility, or vaccine escape warranting VOC status—unlike prior threats like Delta or Omicron. Ongoing genomic sequencing, annual vaccine updates (e.g., LP.8.1-adapted for 2025–2026), and low case hospitalization rates underscore COVID's endemic stabilization, with WHO's May 2026 antigen deliberations focusing on existing VOIs and VUMs rather than novel alarms. Unexpected immune evasion could shift odds, but current evidence favors continuity.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$238,503 Vol.
$238,503 Vol.
$238,503 Vol.
$238,503 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Market Opened: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus prices "No" at 82.5% for a new COVID variant of concern before 2027, reflecting the World Health Organization's stringent criteria unmet by recent SARS-CoV-2 subvariants despite vigilant global surveillance. The highly mutated BA.3.2 ("Cicada") lineage, a variant under monitoring with over 70 spike protein changes, surged in U.S. wastewater across 31 states and Europe through April 2026 but shows no elevated severity, transmissibility, or vaccine escape warranting VOC status—unlike prior threats like Delta or Omicron. Ongoing genomic sequencing, annual vaccine updates (e.g., LP.8.1-adapted for 2025–2026), and low case hospitalization rates underscore COVID's endemic stabilization, with WHO's May 2026 antigen deliberations focusing on existing VOIs and VUMs rather than novel alarms. Unexpected immune evasion could shift odds, but current evidence favors continuity.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions